Business
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nOncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnsbtb0{\nBORDER-BOTTOM:black 0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n\n\n\n\n\n\n\nCanada NewsWire\nEDMONTON, May 24, 2017\n\n\n\nEDMONTON, May 24, 2017 /CNW/ - OncoQuest Inc. (\"OncoQuest\"), a privately held, biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the presentation of initial safety and efficacy data from the company's multicenter, randomized Phase 2 study in patients with newly diagnosed advanced ovarian cancer at the upcoming 2017 ASCO (American Society of Clinical Oncology) Meeting in Chicago, Illinois, USA. \n\n\n\n\nDate and Time:\n\n\nSaturday, June 3, 2017, 1:15 p.m. – 4:45 p.m. CDT\n\n\n\nAbstract Number:\n\n\n5536\n\n\n\nLocation:\n\n\nHall A\n\n\n\nPoster Board:\n\n\nBoard #358\n\n\n\nSession:\n\n\nGynecologic Cancer\n\n\n\"We are pleased to share these initial results from our phase 2 study evaluating our lead drug, oregovomab, an anti-CA125 murine monoclonal antibody in scheduled combination with standard of care chemotherapy (carboplatin and paclitaxel) compared to standard of care alone in ovarian cancer patients in the front-line or initial treatment setting,\" said Dr. Madi Madiyalakan, CEO of OncoQuest.\n\nThe study enrolled 97 patients (95 patients evaluable) from eight centers in Italy and five in the U....